An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Pediatric Subjects

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00116662

Enrollment

Registered

2005-07-01

Start date

2005-03-31

Completion date

Unknown

Last updated

2007-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Warts

Keywords

Wart(s), Common Wart(s), Children, Pediatric, 3M Pharmaceuticals, Resiquimod

Brief summary

The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for up to twelve weeks. A second purpose is to evaluate the safety of the drug.

Interventions

DRUGResiquimod

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

3 Years to 11 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of common wart(s) * Ages between 3 to 11

Exclusion criteria

* Other types of wart(s), ie. plantar * Currently participating in another clinical study * Chronic viral hepatitis B or C

Design outcomes

Primary

Measure	Time frame
Clearance of treated common wart(s)	—

Secondary

Measure	Time frame
Partial clearance of treated common wart(s)	—
Wart recurrence	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026